UAB was part of a groundbreaking trial that is believed to be the first time it has been proved that the risk of mild cognitive impairment and dementia can be reduced through high blood-pressure treatment.
Significant novel findings published by UAB researchers established verapamil as a successful therapeutic approach to target loss of beta cell function caused by Type 1 diabetes.
Biomedical scientists and engineers can participate in a nationwide program that helps take their discoveries from the research lab to the clinical setting.
A diabetes drug suggests potential therapy for idiopathic pulmonary fibrosis, based on research with human lung fibroblasts and a mouse model of lung fibrosis.
In a large-scale analysis, Jeremy Blackburn, Ph.D., and collaborators found that the misuse of web archive services cause loss of ad revenue for popular news websites.
By using an injected biomarker, researchers are able to have a more accurate reading of kidney function in a clinical setting in half the time it used to take.
UAB researchers have identified a subgroup of heart failure patients with reductive stress who may be less responsive or even harmed by antioxidants, which could lead to personalized treatment and better outcomes.
UAB is an Equal Employment/Equal Educational Opportunity Institution dedicated to providing equal opportunities and equal access to all individuals regardless of race, color, religion, ethnic or national origin, sex (including pregnancy), genetic information, age, disability, religion, sexual orientation, gender identity, gender expression, and veteran’s status. As required by Title IX, UAB prohibits sex discrimination in any education program or activity that it operates. Individuals may report concerns or questions to UAB’s Assistant Vice President and Senior Title IX Coordinator. The Title IX notice of nondiscrimination is located at uab.edu/titleix.